Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study

M. Rudin, Charles; M. Awad, Mark; Navarro, Alejandro; Gottfried, Maya; Peters, Solange; Csőszi, Tibor; Cheema, Parneet; Rodríguez‐Abreu, Delvys; Wollner, Mirjana; Chih‐Hsin Yang, James; Mazières, Julien; Orlandi, Francesco; Luft, Alexander; Gümüş, Mahmut; Kato, Terufumi; P. Kalemkerian, Gregory; Luo, Yiwen; Ebiana, Victoria; Catherine Pietanza, M.; Ryun Kim, Hye; behalf of the KEYNOTE-604 Investigators, on

doi:10.1200/jco.20.00793

Public

Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study

Published in Journal of Clinical Oncology • May 29, 2020

Authors:

Charles M. Rudin

Mark M. Awad

Alejandro Navarro

Abstract

PURPOSE Pembrolizumab monotherapy has shown antitumor activity in patients with small-cell lung cancer (SCLC). The randomized, double-blind, phase III KEYNOTE-604 study compared pembrolizumab plus etoposide and platinum (EP) with placebo plus EP for patients with previously untreated extensive-stage...

Subject

Pembrolizumab

Medicine

Placebo

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!